Trial Profile
Proprietary Information - Exploratory (Non-confirmatory) Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs MK 0686 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 08 Oct 2006 New trial record.